These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 21933639

  • 1. Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation.
    Novak S, Anić B, Anić F, Cerovac M, Cikeš N.
    Acta Dermatovenerol Croat; 2011; 19(3):156-60. PubMed ID: 21933639
    [Abstract] [Full Text] [Related]

  • 2. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 3. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 5. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 6. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M, Graninger WB, Steiner G, Smolen JS.
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [Abstract] [Full Text] [Related]

  • 8. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [Abstract] [Full Text] [Related]

  • 9. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA.
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [Abstract] [Full Text] [Related]

  • 10. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [Abstract] [Full Text] [Related]

  • 11. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P.
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [Abstract] [Full Text] [Related]

  • 12. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 13. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N.
    Arthritis Res Ther; 2004 Mar; 6(6):R535-43. PubMed ID: 15535831
    [Abstract] [Full Text] [Related]

  • 14. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
    D'Alessandro G, Bianco MR, Politis S, Ferrandina C, Rossi G, Altomare E.
    Reumatismo; 2006 Mar; 58(1):59-61. PubMed ID: 16639489
    [Abstract] [Full Text] [Related]

  • 15. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS.
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [Abstract] [Full Text] [Related]

  • 16. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T, Pincus T.
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [Abstract] [Full Text] [Related]

  • 17. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M, Rauch J, Armstrong M, Fitzcharles MA.
    J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
    [Abstract] [Full Text] [Related]

  • 18. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 19. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study].
    Caramaschi P, Canestrini S, Biasi D, Carletto A, Scambi C, Scarperi A, Bambara LM.
    Recenti Prog Med; 2002 Jan; 93(1):19-24. PubMed ID: 11850995
    [Abstract] [Full Text] [Related]

  • 20. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G.
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.